BLADDER CANCER: Edited by Siamak DaneshmandTrimodality therapy for bladder cancer modern management and future directionsPham, Anthony; Ballas, Leslie K.Author Information Department of Radiation Oncology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA Correspondence to Leslie K. Ballas, MD, University of Southern California, Keck School of Medicine, Department of Radiation Oncology, 1441 Eastlake Ave., Norris G350, Los Angeles, CA 90033, USA. Tel: +1 323 865 3050; fax: +1 323 865 0000; e-mail: email@example.com Current Opinion in Urology: May 2019 - Volume 29 - Issue 3 - p 210-215 doi: 10.1097/MOU.0000000000000601 Buy Metrics Abstract Purpose of review This review examines both trimodality therapy (TMT) in the definitive management of bladder cancer as well as the use of adjuvant radiotherapy for bladder cancer with a specific focus on publications from the last 2 years. Recent findings TMT is an effective management strategy for muscle invasive bladder cancer with outcomes similar to radical cystectomy. Effectiveness of this strategy exists in variant histologies and can be personalized with use of biomarkers. There is a role for adjuvant radiotherapy in locally advanced bladder cancer, especially in the age of improved imaging and modern radiotherapy techniques. Summary This review should provide the reader data necessary to support use of TMT and adjuvant radiation therapy in their clinic. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.